Skip to main content
Premium Trial:

Request an Annual Quote

UnitedHealthcare to Reimburse for NanoString's Prosigna Breast Cancer Test

NEW YORK (GenomeWeb) – NanoString Technologies said today that it has been told by Laboratory Corporation of America that UnitedHealthcare will reimburse for testing services from LabCorp based on NanoString's Prosigna Breast Cancer Gene Signature Assay.

In a US Securities and Exchange Commission document, NanoString added that UnitedHealthcare is the first major commercial healthcare insurer to confirm coverage for Prosigna testing services. The insurer, which says on its website that it provides services and products to 70 million Americans, will not require preauthorization for the test for any breast cancer patient who meets the Prosigna clinical criteria as defined by the test's package insert.

Earlier in the week, NanoString announced that its second quarter revenues rose 51 percent year over year. Despite the spike, Leerink Partners analyst Dan Leonard lowered his price target on the company's shares to $21 from $23 and cited concerns about NanoString's ability to secure reimbursement from payors, especially from Medicare.

NanoString's shares fell 10 percent yesterday after the firm released its financial results and held its quarterly conference call. But its stock partially rebounded in Thursday morning trade on the Nasdaq, up 4 percent to $11.45.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.